-
公开(公告)号：US20140341851A1
公开(公告)日：2014-11-20
申请号：US14245001
申请日：2014-04-04
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： YAO-LING QIU , Ce Wang , Xiaowen Peng , Hui Cao , Lu Ying , Xuri Gao , Bin Wang , Yat Sun Or
IPC: C07D498/10 , A61K31/4184 , C07D401/14 , A61K31/444 , C07D405/14 , A61K31/4545 , A61K31/5377 , A61K31/496 , C07F9/6506 , A61K31/675 , C07D487/08 , A61K31/506 , C07D409/14 , C07D413/14 , A61K31/422 , C07D491/107 , A61K31/517 , C07D417/14 , A61K45/06 , C07D403/14
CPC classification number: C07D498/10 , A61K31/13 , A61K31/4184 , A61K31/422 , A61K31/427 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K31/675 , A61K31/7056 , A61K38/19 , A61K38/21 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/08 , C07D491/107 , C07F9/65583 , A61K2300/00 , A61K39/12
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
公开(公告)号：US09000020B2
公开(公告)日：2015-04-07
申请号：US13663741
申请日：2012-10-30
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yao-Ling Qiu , Ce Wang , Lu Ying , Xiaowen Peng , Yat Sun Or
IPC: C07D403/10 , A61K31/4184 , C07D403/14 , A61K31/427 , A61K31/444 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K38/21 , A61K45/06 , C07F9/6558 , A61K31/46 , A61K31/517 , C07D401/14 , C07D413/14 , C07D451/02
CPC classification number: C07D403/14 , A61K31/4184 , A61K31/427 , A61K31/444 , A61K31/46 , A61K31/496 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K31/695 , A61K38/21 , A61K45/06 , C07D401/14 , C07D413/14 , C07D451/02 , C07F9/65583 , A61K2300/00
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Abstract translation: 本发明公开了式（I）化合物或其药学上可接受的盐，酯或前药：其抑制含RNA病毒，特别是丙型肝炎病毒（HCV）。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US08921573B2
公开(公告)日：2014-12-30
申请号：US14253976
申请日：2014-04-16
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Datong Tang , Guoyou Xu , Xiaowen Peng , Lu Ying , Ce Wang , Hui Cao , Jiang Long , In Jong Kim , Guoqiang Wang , Yao-Ling Qiu , Yat Sun Or
IPC: C07D403/14
CPC classification number: C07D403/14
Abstract: The present invention relates to processes and intermediates for the preparation of novel benzimidazole derivatives, especially in the synthesis of hepatitis C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (I-a):
Abstract translation: 本发明涉及制备新型苯并咪唑衍生物的方法和中间体，特别是在丙型肝炎病毒NS5A抑制剂的合成中。 特别地，本发明涉及制备式（I-a）化合物的方法和中间体：
-
公开(公告)号：US20140316143A1
公开(公告)日：2014-10-23
申请号：US14253976
申请日：2014-04-16
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Datong Tang , Guoyou Xu , Xiaowen Peng , Lu Ying , Ce Wang , Hui Cao , Jiang Long , In Jong Kim , Guoqiang Wang , Yao-Ling Qiu , Yat Sun Or
IPC: C07D403/14
CPC classification number: C07D403/14
Abstract: The present invention relates to processes and intermediates for the preparation of novel benzimidazole derivatives, especially in the synthesis of hepatitis C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (I-a):
Abstract translation: 本发明涉及制备新型苯并咪唑衍生物的方法和中间体，特别是在丙型肝炎病毒NS5A抑制剂的合成中。 特别地，本发明涉及制备式（I-a）化合物的方法和中间体：
-
公开(公告)号：US10752611B2
公开(公告)日：2020-08-25
申请号：US16007194
申请日：2018-06-13
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Yat Sun Or
IPC: C07D403/10 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/08 , C07F9/6558 , C07F7/18
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
Patent Agency Ranking
公开(公告)号：US20200002314A1
公开(公告)日：2020-01-02
申请号：US16007194
申请日：2018-06-13
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Yat Sun Or
IPC: C07D403/10 , C07D403/14 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07F7/18 , C07D409/14 , C07F9/6558 , C07D487/08
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
公开(公告)号：US20140193363A1
公开(公告)日：2014-07-10
申请号：US14155653
申请日：2014-01-15
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Yat Sun Or
IPC: C07D403/14 , A61K38/21 , A61K39/00 , A61K31/675 , A61K31/5377 , A61K31/496 , A61K31/4709 , A61K31/454 , A61K31/4439 , A61K31/4245 , A61K31/427 , A61K31/422 , A61K31/41 , A61K31/4196 , A61K31/4184 , C07D413/14 , C07D401/14 , C07F9/6558 , C07D417/14 , C07D405/14 , C07D409/14 , C07D487/08 , A61K38/19
CPC classification number: C07D403/14 , A61K31/41 , A61K31/4184 , A61K31/4196 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/675 , A61K31/7056 , A61K38/19 , A61K38/21 , A61K38/212 , A61K38/215 , A61K38/217 , A61K39/00 , A61K45/06 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/08 , C07F9/65583 , A61K2300/00 , A61K39/12
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Abstract translation: 本发明公开了式（I）化合物或其药学上可接受的盐，酯或前药：其抑制含RNA病毒，特别是丙型肝炎病毒（HCV）。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US10017499B2
公开(公告)日：2018-07-10
申请号：US15339000
申请日：2016-10-31
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Yat Sun Or
IPC: C07D498/10 , C07D403/04 , A61K31/4184 , C07D403/14 , C07D401/14 , C07D405/14 , C07D417/14 , C07D413/14 , C07D409/14 , C07D487/08 , C07F9/6558
CPC classification number: C07D403/14 , A61K31/41 , A61K31/4184 , A61K31/4196 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/675 , A61K31/7056 , A61K38/19 , A61K38/21 , A61K38/212 , A61K38/215 , A61K38/217 , A61K39/00 , A61K45/06 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/08 , C07F9/65583 , A61K2300/00 , A61K39/12
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
公开(公告)号：US09765087B2
公开(公告)日：2017-09-19
申请号：US14245001
申请日：2014-04-04
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Hui Cao , Lu Ying , Xuri Gao , Bin Wang , Yat Sun Or
IPC: C07D498/10 , C07D403/14 , A61K31/4184 , C07D401/14 , A61K31/444 , C07D405/14 , A61K31/4545 , A61K31/5377 , A61K31/496 , A61K31/675 , C07D487/08 , A61K31/506 , C07D409/14 , C07D413/14 , A61K31/422 , C07D491/107 , A61K31/517 , C07D417/14 , A61K45/06 , A61K38/19 , A61K38/21 , A61K31/427 , A61K31/7056 , C07F9/6558 , A61K31/13
CPC classification number: C07D498/10 , A61K31/13 , A61K31/4184 , A61K31/422 , A61K31/427 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K31/675 , A61K31/7056 , A61K38/19 , A61K38/21 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/08 , C07D491/107 , C07F9/65583 , A61K2300/00 , A61K39/12
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
公开(公告)号：US20170114046A1
公开(公告)日：2017-04-27
申请号：US15339000
申请日：2016-10-31
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Yat Sun Or
IPC: C07D403/14 , C07D405/14 , C07F9/6558 , C07D413/14 , C07D409/14 , C07D487/08 , C07D401/14 , C07D417/14
CPC classification number: C07D403/14 , A61K31/41 , A61K31/4184 , A61K31/4196 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/675 , A61K31/7056 , A61K38/19 , A61K38/21 , A61K38/212 , A61K38/215 , A61K38/217 , A61K39/00 , A61K45/06 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/08 , C07F9/65583 , A61K2300/00 , A61K39/12
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.027 seconds)
